MTOR and melanoma: Finally, recent data on the prime role of the tyrosine kinases SRC and the AKT/mTOR axis in melanoma progression [55,56] highlights the unique implication of 3, 3′- (3, 5-DCPBC) as a promising small molecule drug candidate.